GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (NAS:OPTN) » Definitions » Net Income (Continuing Operations)

OptiNose (OptiNose) Net Income (Continuing Operations) : $-35.48 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is OptiNose Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. OptiNose's Net Income (Continuing Operations) for the three months ended in Dec. 2023 was $-9.97 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was $-35.48 Mil.

OptiNose Net Income (Continuing Operations) Historical Data

The historical data trend for OptiNose's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptiNose Net Income (Continuing Operations) Chart

OptiNose Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only -110.05 -99.79 -82.30 -74.83 -35.48

OptiNose Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.15 -18.85 2.63 -9.29 -9.97

OptiNose Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OptiNose  (NAS:OPTN) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

OptiNose Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of OptiNose's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

OptiNose (OptiNose) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (NAS:OPTN) » Definitions » Net Income (Continuing Operations)
Comparable Companies
MRMD ELTP ZOM EBS AQST ETON ALIM ESPR EGRX CHHE ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
0OP:Germany
Address
1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067
Website
https://www.optinose.com
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
Executives
Marino Michael F Iii officer: Chief Legal Officer & Corp Sec C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Ramy A Mahmoud officer: President & COO 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Peter K Miller director, officer: Chief Executive Officer C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087
Mvm Partners, Llc 10 percent owner OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Michele Janis officer: Acting Chief Financial Officer 1020 STONY HILL ROAD, YARDLEY PA 19067
Victor M Clavelli officer: Chief Commercial Officer 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Paul Jr. Spence officer: Chief Commercial Officer 1507 POWNAL DRIVE, YARDLEY PA 19067
Anthony J Krick officer: Chief Accounting Officer 1020 STONY HILL ROAD, YARDLEY PA 19067
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Kyle Dempsey director OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Eric Bednarski director OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Partners Llp Mvm 10 percent owner 30 ST. GEORGE STREET, LONDON X0 W1S SFH
Keith A. Goldan officer: Chief Financial Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Joseph C Scodari director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080